Motif Bio Share Discussion Threads

[lionheart69uk1] 25/3/2019 12:53

Popping downwards I fear

[newtothisgame3] 25/3/2019 12:31

Going 2 pop

[small crow] 25/3/2019 12:24

dave, not sure if you refer to me but don't use twitter, so carry on with your conspiracies!

[depjoe] 25/3/2019 12:06

desperate dave
so why dave do you keep changing your name
why are you always trying to hide something

[newtothisgame3] 25/3/2019 11:40

MTFB Motif Bio PLC says
institutional and other investors --- is it another pharma coming onboard OTHER INVESTORS

[buywell3] 25/3/2019 11:28

Wonder if they will get over 5p

[dave4545] 25/3/2019 11:27

What's so great about that post then @smallcappick apart from the fact it was you who wrote in then you go to twitter to retweet it ?

I've seen some desperate stuff over the years but your ramps now are right up there at the top. You go to some lengths to try and fool others.

[newtothisgame3] 25/3/2019 11:17

50K block buyer

[newtothisgame3] 25/3/2019 11:14

Dont rule out the news later today at 7p+ then watch the rush

[lionheart69uk1] 25/3/2019 10:45

Letmepass, you are well off the mark. It will be 7.25p minimum

[small crow] 25/3/2019 10:36

Looks like people suspect the raise is at least 8p?

[letmepass] 25/3/2019 10:15

Fundraise at 5p

[bermudashorts] 25/3/2019 09:32

RNS on 20th March caused rise in the share price but for the rest of the month it had been sitting in the 5's and 6's - perhaps a more likely level for funding. We shall see.

[lionheart69uk1] 25/3/2019 08:26

More Betaville nonsense. They write absolute garbage.

[tomboyb] 25/3/2019 08:25

If u like Biotech OVG rns Phase III trial meets primary endpoint -

Capped at a mere 7million -

[newtothisgame3] 25/3/2019 07:45

Correction opened 9.4p on Friday

[newtothisgame3] 25/3/2019 07:42

it opened at 9p on Friday so a placing at 8p sounds about correct boom time

[bad gateway] 25/3/2019 07:36

At this level that wouldn't be so bad imo, if true, £2.2m UKPounds raised at c. 6.75p. (25% 0ff Fridays opening 9p level)
Would set them up well for the Fed meeting.

[pjj71] 25/3/2019 07:27

hxxps://www.betaville.co.uk/news/rare-alert-motif-bio-said-to-have-kicked-off-3-mil/

ouch

[newtothisgame3] 23/3/2019 21:42

The effects of iclaprim on exotoxin production in methicillin-resistant and vancomycin-intermediate Staphylococcus aureus Cover date: 01/03/2019

[newtothisgame3] 23/3/2019 14:52

Conclusion

We’re glad to see that the FDA has accepted the NDA filing for iclaprim and that a PDUFA data of Feb. 13, 2019 has been assigned. The FDA has not indicated that an advisory committee (“AdComm”) meeting will be taking place for iclaprim, but it is not inconceivable that one will end up being scheduled. However, with the strong data from both REVIVE-1 and REVIVE-2, we don’t believe that an AdComm, were it to take place, would be a negative.

There are an estimated 3.6 million people hospitalized with ABSSSI every year. We conservatively estimate that 20% of patients have renal insufficiency, based on published data (Halilovic et al., 2012). We believe iclaprim could attain peak market share among these patients of 20%. We model for a full course of treatment costing $3000 and an inflation rate of 2%, which leads to peak sales of approximately $500 million in the U.S. Outside the U.S., we believe Motif will sign a commercialization agreement that will result in an average 15% royalty on net sales, which we estimate will peak at approximately $225 million. Using a 90% probability of approval and a 15% discount rate leads to a net present value for iclaprim in ABSSSI of $475 million. After factoring in the company’s cash position, potential cash from the exercise of outstanding warrants, and dividing by the fully diluted ADS share count of 18.6 million leads to a valuation of $28 per share. The stock continues to trade at a significant discount to our valuation, thus offering investors plenty of upside at the current price.

[bocase] 21/3/2019 19:48

...and now jaknife, the meeting date has been set so why re post an out of date RNS...no doubt you are one of these that thinks going short and trying to undermine confidence in a British company is a good thing to do